TuHURA Biosciences (NASDAQ:HURA – Get Free Report) was upgraded by equities research analysts at RODMAN&RENSHAW to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.
Other equities research analysts have also recently issued reports about the stock. Maxim Group started coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price objective on the stock. Rodman & Renshaw began coverage on TuHURA Biosciences in a research report on Thursday. They set a “buy” rating and a $11.00 price objective for the company.
Read Our Latest Analysis on HURA
TuHURA Biosciences Stock Performance
About TuHURA Biosciences
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Read More
- Five stocks we like better than TuHURA Biosciences
- Ride Out The Recession With These Dividend Kings
- Micron Stock Under $100: Seize the AI-Driven Upside
- Insider Buying Explained: What Investors Need to Know
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- What is the NASDAQ Stock Exchange?
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
